Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized two-part study of MK-4827 given with temozolomide in participants
with advanced cancer. In Part A of the study, the dose-limiting toxicities (DLTs) and the
maximum tolerated dose (MTD) of MK-4827 when combined with temozolomide will be found by
increasing the MK-4827 dose level in successive cohorts. In Part B of the study, participants
with advanced glioblastoma multiforme and advanced melanoma will be enrolled to further
evaluate the tolerability and efficacy of the MK-4827 + temozolomide combination.